You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
McKesson
Moodys
Merck
Harvard Business School

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,669,281

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,669,281 protect, and when does it expire?

Patent 8,669,281 protects VUMERITY and is included in one NDA.

This patent has forty-six patent family members in twenty-five countries.

Summary for Patent: 8,669,281
Title:Prodrugs of fumarates and their use in treating various diseases
Abstract: The present invention provides compounds of formula (I), ##STR00001## wherein: R.sub.1 is unsubstituted C.sub.1-C.sub.6 alkyl; L.sub.a is substituted or unsubstituted C.sub.1-C.sub.6 alkyl linker, substituted or unsubstituted C.sub.3-C.sub.10 carbocycle, substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S; and R.sub.2 and R.sub.3 are each, independently, H, substituted or unsubstituted C.sub.1-C.sub.6 alkyl, or substituted or unsubstituted C.sub.6-C.sub.10 aryl; or alternatively, R.sub.2 and R.sub.3, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S or a substituted or unsubstituted heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S. The invention also provides pharmaceutical compositions and methods for treating neurological diseases, such as multiple sclerosis.
Inventor(s): Zeidan; Tarek A. (Watertown, MA), Duncan; Scott (Bedford, MA), Hencken; Christopher P. (Boston, MA), Wynn; Thomas Andrew (Lexington, MA), Sanrame; Carlos N. (Lexington, MA)
Assignee: Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:14/032,736
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,669,281

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biogen VUMERITY diroximel fumarate CAPSULE, DELAYED RELEASE;ORAL 211855-001 Oct 29, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Mallinckrodt
Colorcon
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.